First-line treatment for MSI-high stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you can sign consent before any screening tests.
- Your cancer is confirmed dMMR (mismatch repair defect on biopsy test) and is HER2 negative, or HER2 positive only if trastuzumab can’t be used.
- Your cancer is metastatic or inoperable, and you have at least one measurable tumor spot on scans.
- You have not had prior chemotherapy or radiotherapy for metastatic/inoperable stomach or esophagus cancer (some limited palliative radiation is allowed).
- You can provide a biopsy that can be re-tested for study purposes, and you’re able to do study visits (ECOG 0–2).
- Your blood and organ tests are good enough (for example, adequate white blood cells, platelets, kidney function, and liver enzymes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a new immunotherapy medicine (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for people with a specific type of stomach cancer (MSI-H/dMMR) that can be removed by surgery. The goal is to see if this combination helps shrink the tumor and improve outcomes before surgery.
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a combination of four treatments (two investigational drugs, a targeted therapy, and chemotherapy) as a first-line option for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.